Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-01
2007-05-01
Siew, Jeffrey (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S663000
Reexamination Certificate
active
09976961
ABSTRACT:
Disclosed are a method of inducing apoptosis of a malignant cell, which employs a calcium-activated potassium channel (KCa) activator and is useful for treating a malignant tumor in a human subject. Also disclosed are methods of selectively inhibiting the proliferation of malignant cells compared to non-malignant cells in a mixed population of malignant and non-malignant cells and of inhibiting the growth of a malignant tumor, such as a glial tumor, in a mammalian subject. A kit for inducing apoptosis of malignant cells is also disclosed.
REFERENCES:
patent: 5112596 (1992-05-01), Malfroy-Camine
patent: 5124146 (1992-06-01), Neuwelt
patent: 5215985 (1993-06-01), Murphy et al.
patent: 5256688 (1993-10-01), Grover et al.
patent: 5262419 (1993-11-01), Aberg et al.
patent: 5314887 (1994-05-01), Aldrich et al.
patent: 5399587 (1995-03-01), Garcia et al.
patent: 5416097 (1995-05-01), Erhardt et al.
patent: 5527527 (1996-06-01), Friden
patent: 5527778 (1996-06-01), Black
patent: 5578599 (1996-11-01), Diani et al.
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5677344 (1997-10-01), Greenfield et al.
patent: 5679706 (1997-10-01), D'Alonzo et al.
patent: 5686416 (1997-11-01), Kozarich et al.
patent: 5693627 (1997-12-01), Schieven
patent: 5695751 (1997-12-01), Friedman et al.
patent: 5760230 (1998-06-01), Schohe-Loop et al.
patent: 5869509 (1999-02-01), Romine et al.
patent: 5877210 (1999-03-01), Schieven
patent: 5922735 (1999-07-01), Sit et al.
patent: 2003/0036199 (2003-02-01), Bamdad et al.
patent: 0 351 767 (1990-01-01), None
patent: 0 555 681 (1993-08-01), None
patent: 0 575 749 (1993-12-01), None
patent: WO 91/16355 (1991-10-01), None
patent: WO 97/18332 (1997-05-01), None
patent: WO 97/31654 (1997-09-01), None
patent: WO 00/23102 (2000-04-01), None
Gulbins et al. (Proc. Natl. Acad. Sci. USA 1997, 94: 7661-7666).
Nietsch et al. (J. Biol. Chem. 2000, 275 (27): 20556-20561).
Lauritzen et al. (J. Neurochem. 1997, 69: 1570-1579).
Choi et al. (Cancer Letters 1999, 147: 85-93).
Kim et al. (Pharmacology 2000, 60 (2): 74-81).
Wang et al. (Am. J. Physiol. Heart Cir. Physiol. 2004; 287: H2070-H2077.
Yamada et al. (Cancer Research 1987; 47: 2123-2128.
Adeagbo, A. S., 1-Ethyl-2-benzimidazolinone stimulates endothelial K (Ca) channels and nitric oxide formation in rat mesenteric vessels,Eur J. Pharmacol, 379(2-3):151-9 (Aug. 27, 1999). Abstract Only.
Akar, F. et al, Protective effect of cromakalim and diazoxide, and proulcerogenic effect of glibenclamide on indomethacin-induced gastric injury,Eur J. Pharmacol, 374(3):461-70 (Jun. 25, 1999). Abstract Only.
Andrade, S.P. et al., Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors,Int J Exp Pathol, 79(6):425-32 (Dec. 1998). Abstract Only.
Armstead. W.M., Contribution of kca channel activation to hypoxic cerebrovasodilatation does not involve NO,Brain Res. 799(1):44-8 (Jul. 13, 1998). Abstract Only.
Bang, L. et al., Nitroglycerin-mediated vasorelaxation is modulated by endothelial calcium-activated potassium channels,Cardiovasc Res, 43(3):772-8 (Aug. 15, 1999). Abstract Only.
Becker, E.M. et al., The vasodilator-stimulated phosphoprotein (VASP):target of YC-1 and nitric oxide effects in human and rat platelets,J. Cardiovasc Pharmacol, 35(3):390-7 (Mar. 2000). Abstract Only.
Black, K.L. et al., Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C4,J. Neurosurg, 72:912-916 (Jun. 1990).
Bowman, T. et al., STATs in oncogenesis,Oncogene, 19(21):2474-88 (May 15, 2000). Abstract Only.
Brian, J.E., Jr. et al., Recent insights into the regulation of cerebral circulation,Clin Exp Pharmacol Physiol, 23(6-7):449-57 (Jun.-Jul. 1996). Abstract Only.
Brismar, T. et al., Mechanism of high K+ and Ti+ uptake in cultured human glioma cells,Cell Mol Neurobiol. 15(3):351-60 (Jun. 1995). Abstract Only.
Brismar, T. et al., Thallium-201 uptake relates to membrane potential and potassium permeability in human glioma cells,Brain Res, 500(1-2):30-6 (Oct. 23, 1989). Abstract Only.
Burg, M.A. et al., NG2 proteoglycan-binding peptides target tumor neovasculature,Cancer Res, 59(12):2869-74 (Jun. 15, 1999). Abstract Only.
Burrows, F.J. et al., Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature,Proc Natl Acad Sci U S A, 90(19):8996-9000 (Oct. 1, 1993). Abstract Only.
Butt, A.M., Effect of histamine and antagonists on electrical resistance across the blood-brain barrier in rat brain-surface microvessels,Brain Res, 569(1):100-5 (Jan. 8, 1992). Abstract Only.
Butt, A.M., Effect of inflammatory agents on electrical resistance across the blood-brain barrier in pial microvessels of anaesthetized rats,Brain Res, 696(1-2):145-50 (Oct. 23, 1995). Abstract Only.
Butt, E. et al., Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS,Br J. Pharmacol, 116(8):3110-6 (Dec. 1995). Abstract Only.
Bychkov, R. et al., Calcium-activated potassium channels and nitrate-induced vasodilation in human coronary arteries,J. Pharmacol Exp Ther, 285(1):293-8 (Apr. 1998). Abstract Only.
Cai, S. et al., Single-channel characterizationof the pharmacological properties of the K(Ca2+) channel of intermediate conductance in bovine aortic endothelial cells,J Membr Biol, 163(2):147-58 (May 15, 1998). Abstract Only.
Chang, S.S. et al., Five different anti-prostate-specific membrane antigen (PSMA0 antibodies confirm PSMA expression in tumor-associated neovasculature,Cancer Res, 59(13):3192-8 (Jul. 1, 1999). Abstract Only.
Chaplin, D.J. et al., Anti-vascular approaches to solid tumour therapy: evaluationof combretastatin A4 phosphate,Anticancer Res. 19(1A):189-95 (Jan.-Feb. 1999). Abstract Only.
Chassande. O. et al., The Na+/K+/Cl- cotransport in C6 glioma cells. Properties and role in volume regulation,Eur J. Biochem, 171(3):425-33 (Feb. 1, 1988). Abstract Only.
Chess-Williams, R. et al., In vitro investigationof the bladder-vascular selectivity of levcromakalim and YM934 in human tissues,BJU Int, B3(9):1050-4 (Jun. 1999). Abstract Only.
Chen, C.H. et al., Ntric oxide activates Ca2+-activated K+ channels in cultured bovine adrenal chromaffin cells,Neurosci Lett, 248(2):127-9 (May 29, 1998). Abstract Only.
Dark. G.G. et al., Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature,Cancer Res, 57 (10):1829-34 (May 15, 1997). Abstract Only.
Denekamp, J. et al., Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?Adv Enzyme Regul, 38:281-99 (1998). Abstract Only.
Desai, S.B. et al., Tumor angiogenesis and endothelial cell modulatory factors,J. Immunother, 22(3):186-211 (May 1999). Abstract Only.
D'hahan, N. et al., A transmembrane domain of the sulfonylurea receptor mediates activation of ATP-sensitive K(+) channels by K(+) channel openers,Mol Pharmacol. 56(2):308-15 (Aug. 1999). Abstract Only.
Duda, T. et al., Mutations in the Rod Outer Segment Membrane Guanylate Cyclase in a Cone-Rod Dystrophy Cause Defects in Calcium Signaling,Biochemistry, 38(42):132912-13919 (Oct. 19, 1999), Abstract Only.
Faraci, F.M. et al., Responses of cerebral arterioles to N-methyl-D-aspartate and activation of ATP-sensitive potassium channels in old rats,Brain Res, 654(2):349-51 (Aug. 22, 1994). Abstract Only.
Faraci, F.M. et al., Potassium channels and the cerebral circulation,Clin Exp Pharmacol Physiol, 23(12):1091-5 (Dec. 1996). Abstract Only.
Feelisch, Martin, The use of nitric oxide donors in pharmacological studies,Naunyn-Schmiedeberg's Arch Pharmacol, 358:113-122 (Springer-Veriag 1998).
Ferrero, R. et al., Comparative effects of several nitric oxide donors on intracellular cyclic GMP levels in bovine chromaffin cells: correlation with nitric oxide production,Br J. Pharmacol. 127(3):779-87 (Jun. 1999). Abstract Only.
Friebe, A. et al., Mechanism of YC-1-induced activation of soluble guanylyl cyclase,Mol Pharmacol, 53(1):123-7 (Jan. 1998). Abstract Only.
Fukao, M. et al., Cyclic GMP-dependent protein kinase activates cloned
Black Keith L.
Ningaraj Nagendra S.
Cedars-Sinai Medical Center
Davis , Wright, Tremaine, LLP
Fetterolf Brandon
Levy Seth D.
Siew Jeffrey
LandOfFree
Method for inducing selective cell death of malignant cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inducing selective cell death of malignant cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inducing selective cell death of malignant cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3776615